
ELOX Stock Forecast & Price Target
ELOX Analyst Ratings
Bulls say
Eloxx Pharma is attractive fundamentally because exaluren targets a clearly validated disease mechanism—premature stop-codon readthrough—with strong precedent from aminoglycoside studies and a clean safety profile across 145 subjects in 8 early-stage trials. The most important near-term catalyst is EXACT, where 16-week topline data remain expected in mid-2027 after Phase 2a Alport data showed filtration slit density improved in all 3 patients and collagen IV rose in all 3, while cash of about $62M is guided to last into mid-2028. Longer-term, the 52-week EXPRESS design pushes ADPKD data to 1H 2029 but should strengthen the total kidney volume readout, supporting a platform that could address both the ~4.2K nonsense-mediated Alport and ~37K ADPKD patient opportunities.
Bears say
Eloxx Pharma is burdened by a weak balance sheet, with about $62M in cash, cash equivalents, and marketable securities at the end of 2Q 2026, while it is not expected to be profitable on a continuing basis until 2033, raising the odds of dilutive capital raises. The core programs also face major clinical and regulatory uncertainty: exaluren must still prove meaningful efficacy in Alport and ADPKD, and FDA has already asked for additional evidence linking filtration slit density to proteinuria, while early data showed inconsistent UPCR improvement and limited translation from preclinical findings. Added to that is commercialization risk, since delays in approval or difficulty establishing surrogate endpoints could sharply reduce value, and the early-stage, non-commercial profile leaves the company dependent on future financing and successful trial execution.
This aggregate rating is based on analysts' research of Eloxx Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ELOX Analyst Forecast & Price Prediction
Start investing in ELOX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eloxx Pharmaceuticals Inc (ELOX) Forecast
ELOX Analyst Forecast & Price Prediction
Start investing in ELOX
Order type
Buy in
Order amount
Est. shares
0 shares